UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware

001-36172

22-3106987

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts	02139
(Address of principal executive offices)	(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In a press release dated July 28, 2016, ARIAD Pharmaceuticals, Inc. (the “Company”) announced financial results for the second quarter and six months ended June 30, 2016 and provided an update on corporate developments. A copy of the press release is attached hereto as Exhibit 99.1. The information under the headings “Financial Results for the Quarter and Six Months Ended June 30, 2016”, “Today’s Conference Call at 8:30 a.m. ET” and the condensed consolidated financial information included in the press release are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

In the press release dated July 28, 2016, the Company also provided information on upcoming medical meetings. The information set forth under the heading “Upcoming Medical Meetings” in the press release is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

In the press release dated July 28, 2016, the Company also provided an update on its Iclusig^®, brigatinib and pipeline programs. The second paragraph of the press release and the information set forth under the heading “Recent Progress and Key Objectives,” together with the forward-looking statement disclaimer at the end of the press release, are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

	Exhibit		Description
	99.1		Press release dated July 28, 2016

The press release may contain hypertext links to information on our websites. The information on our websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

The portions of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to such item. The remaining portions of the press release are being furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARIAD Pharmaceuticals, Inc.


		By:	/s/ Manmeet S. Soni
			Manmeet S. Soni
			Executive Vice President, Chief Financial Officer

Date:	July 28, 2016

Exhibit Number	Description

99.1	Press release dated July 28, 2016